Literature DB >> 8849246

Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

G V Doern1, M J Ferraro, A B Brueggemann, K L Ruoff.   

Abstract

Three hundred fifty-two blood culture isolates of viridans group streptococci obtained from 43 U.S. medical centers during 1993 and 1994 were characterized. Included were 48 isolates of "Streptococcus milleri," 219 S. mitis isolates, 29 S. salivarius isolates, and 56 S. sanguis isolates. High-level penicillin resistance (MIC, > or = 4.0 micrograms/ml) was noted among 13.4% of the strains; for 42.9% of the strains, penicillin MICs were 0.25 to 2.0 micrograms/ml (i.e., intermediate resistance). In general, amoxicillin was slightly more active than penicillin. The rank order of activity for five cephalosporins versus viridans group streptococci was cefpodoxime = ceftriaxone > cefprozil = cefuroxime >> cephalexin. The percentages of isolates resistant (MIC, > or = 2 micrograms/ml) to these agents were 15, 17, 18, 20, and 96, respectively. The rates of resistance to erythromycin, tetracycline, and trimethoprim-sulfamethoxazole were 12 to 38%. Resistance to either chloramphenicol or ofloxacin was uncommon (i.e., < 1%). In general, among the four species, S. mitis was the most resistant and "S. milleri" was the most susceptible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849246      PMCID: PMC163225     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Streptococcus mitis and ARDS in neutropenic patients.

Authors:  P H McWhinney; S H Gillespie; C C Kibbler; A V Hoffbrand; H G Prentice
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

2.  Prevention of bacterial endocarditis. Recommendations by the American Heart Association.

Authors:  A S Dajani; A L Bisno; K J Chung; D T Durack; M Freed; M A Gerber; A W Karchmer; H D Millard; S Rahimtoola; S T Shulman
Journal:  JAMA       Date:  1990-12-12       Impact factor: 56.272

3.  Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis.

Authors:  W Kern; K Linzmeier; E Kurrle
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

4.  Streptococcal sepsis in bone marrow transplant patients.

Authors:  J Henslee; B Bostrom; D Weisdorf; N Ramsay; P McGlave; J Kersey
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

5.  Serious infections due to penicillin-resistant strains of viridans streptococci with altered penicillin-binding proteins.

Authors:  J P Quinn; C A DiVincenzo; D A Lucks; R L Luskin; K L Shatzer; S A Lerner
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

6.  Antimicrobial susceptibilities of species of viridans streptococci.

Authors:  A M Bourgault; W R Wilson; J A Washington
Journal:  J Infect Dis       Date:  1979-09       Impact factor: 5.226

7.  Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases.

Authors:  W Kern; E Kurrle; T Schmeiser
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

8.  Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors.

Authors:  P Y Bochud; P Eggiman; T Calandra; G Van Melle; L Saghafi; P Francioli
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079

9.  Streptococcus mitis endocarditis. Report of 17 cases.

Authors:  K B Rapeport; J A Girón; F Rosner
Journal:  Arch Intern Med       Date:  1986-12

10.  Viridans streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci.

Authors:  R B Roberts; A G Krieger; N L Schiller; K C Gross
Journal:  Rev Infect Dis       Date:  1979 Nov-Dec
View more
  48 in total

1.  Incidence of mefA and mefE genes in viridans group streptococci.

Authors:  C Arpin; M H Canron; J Maugein; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

Authors:  J C de Azavedo; L Trpeski; S Pong-Porter; S Matsumura; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  Evaluation of the PASCO strep plus broth microdilution antimicrobial susceptibility panels for testing Streptococcus pneumoniae and other Streptococcal species.

Authors:  M J Mohammed; F C Tenover
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

4.  Antimicrobial susceptibilities and clinical sources of Facklamia species.

Authors:  L LaClaire; R Facklam
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 5.  Miscellaneous catalase-negative, gram-positive cocci: emerging opportunists.

Authors:  Kathryn L Ruoff
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

6.  Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Authors:  Andrea S Gershon; Joyce C S de Azavedo; Allison McGeer; Krystyna I Ostrowska; Deirdre Church; Daryl J Hoban; Godfrey K M Harding; Karl Weiss; Lewis Abbott; Fiona Smaill; Marie Gourdeau; Gilles Murray; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  All detectable high-molecular-mass penicillin-binding proteins are modified in a high-level beta-lactam-resistant clinical isolate of Streptococcus mitis.

Authors:  A Amoroso; D Demares; M Mollerach; G Gutkind; J Coyette
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

8.  Molecular characterization of multidrug resistance in Streptococcus mitis.

Authors:  S M Poutanen; J de Azavedo; B M Willey; D E Low; K S MacDonald
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

9.  Genetic basis of erythromycin resistance in oral bacteria.

Authors:  A Villedieu; M L Diaz-Torres; A P Roberts; N Hunt; R McNab; D A Spratt; M Wilson; P Mullany
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Discrepancy in antimicrobial susceptibility test results obtained for oral streptococci with the Etest and agar dilution.

Authors:  Eiman M Mokaddas; Nathaneal O Salako; Leeba Philip; Vincent O Rotimi
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.